Beam Therapeutics Inc is a biotechnology business based in the US. Beam Therapeutics Inc shares (BEAM) are listed on the NASDAQ and all prices are listed in US Dollars. Beam Therapeutics Inc employs 346 staff and has a trailing 12-month revenue of around $360.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $32.17 |
|---|---|
| 52-week range | $16.95 - $49.50 |
| 50-day moving average | $24.27 |
| 200-day moving average | $26.70 |
| Wall St. target price | $48.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.60 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $32.17 from 2024-07-25
| 1 week (2024-07-19) | 24.02% |
|---|---|
| 1 month (2024-06-27) | 34.15% |
| 3 months (2024-04-26) | 50.47% |
| 6 months (2024-01-26) | 32.44% |
| 1 year (2023-07-27) | 7.92% |
|---|---|
| 2 years (2022-07-27) | -52.56% |
| 3 years (2021-07-27) | 84.37 |
| 5 years (2019-07-23) | N/A |
| Revenue TTM | $360.9 million |
|---|---|
| Gross profit TTM | $-250,674,000 |
| Return on assets TTM | -8.44% |
| Return on equity TTM | -16.09% |
| Profit margin | -37.33% |
| Book value | $11.58 |
| Market Capitalization | $2.1 billion |
TTM: trailing 12 months
We're not expecting Beam Therapeutics Inc to pay a dividend over the next 12 months.
Over the last 12 months, Beam Therapeutics Inc's shares have ranged in value from as little as $16.95 up to $49.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Beam Therapeutics Inc's is 1.871. This would suggest that Beam Therapeutics Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Beam Therapeutics Inc. , a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc. , focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc. , for cardiovascular disease treatments; Sana Biotechnology, Inc. , to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.